caa a22 4500 445335548 CHVBK 20180317142753.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1245/s10434-011-1636-0 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1636-0 Aberrant Gene Methylation Is a Biomarker for the Detection of Cancer Cells in Peritoneal Wash Samples from Advanced Gastric Cancer Patients [Elektronische Daten] [Masatsugu Hiraki, Yoshihiko Kitajima, Yasuo Koga, Tomokazu Tanaka, Jun Nakamura, Kazuyoshi Hashiguchi, Hirokazu Noshiro, Kohji Miyazaki] Purpose: To assess whether gene methylation in peritoneal fluid (PF) is clinically feasible for determining micrometastasis to the peritoneum in gastric cancer. Methods: The gene methylation of BNIP3, CHFR, CYP1B1, MINT25, SFRP2, and RASSF2 were analyzed in 107 specimens of PF by quantitative methylation-specific polymerase chain reaction. All patients were placed into one of 3 groups: group A (n=42), patients with depth of cancer invasion at muscularis propria (MP) or less than MP; group B (n=45), depth of cancer invasion beyond the MP; and group C (n=20), histologically diagnosed peritoneal metastasis or cancer cells cytologically defined in the peritoneal cavity. Patients in both groups A and B were diagnosed as having no cancer cells by peritoneal cytology and histology. Results: The methylation status of the 6 genes was found to be significantly different among the 3 groups (group A, 0-5%; group B, 0-15%; group C, 15-45%; P<0.01). Furthermore, the rate of positive methylation in any of the 6 genes was significantly different in each group (group A, 7%; group B, 20%; group C, 75%; P<0.001). Three of 9 patients in group B with positive methylation in any of 6 genes experienced peritoneal recurrence. On the other hand, only 1 of 36 patients without gene methylation experienced peritoneal recurrence (P<0.05). Conclusions: DNA methylation in PFs is a possible marker detecting occult neoplastic cells on the peritoneum. Methylation analysis along with a cytological examination might therefore improve the positive detection of cancer cells in PF of gastric cancer. Society of Surgical Oncology, 2011 Hiraki Masatsugu Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Kitajima Yoshihiko Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Koga Yasuo Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Tanaka Tomokazu Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Nakamura Jun Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Hashiguchi Kazuyoshi Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Noshiro Hirokazu Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Miyazaki Kohji Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 3013-3019 1068-9265 18:10<3013 2011 18 10434 https://doi.org/10.1245/s10434-011-1636-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1636-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Hiraki Masatsugu Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Kitajima Yoshihiko Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Koga Yasuo Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Tanaka Tomokazu Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Nakamura Jun Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Hashiguchi Kazuyoshi Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Noshiro Hirokazu Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 700 1- Miyazaki Kohji Department of Surgery, Saga University Faculty of Medicine, Saga, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/10(2011-10-01), 3013-3019 1068-9265 18:10<3013 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer